In a breakthrough that could transform paediatric healthcare across India, Jaipur-born health-tech startup Aignosis is redefining how autism is detected—using nothing more than computer vision, machine learning, and a regular webcam.
Founded in 2024, Aignosis has built a non-invasive, five-minute autism screening tool that can be used by paediatricians, preschools, and early-learning centres anywhere in the country. By decoding micro-behaviours such as eye movement, attention shifts, and facial expressions, the AI system delivers an instant risk assessment—helping parents seek early intervention during the most crucial developmental window.
In an exclusive conversation with The Interview World at the Samarth India Conclave & Expo 2025, hosted by Times Network and Hyundai, Aignosis’ Head of Operations Gaural Gupta shared how the innovation works, why early detection matters, and how the tool could close India’s massive diagnosis gap.
A Simple Webcam Test That Spots Early Signs of Autism
For millions of Indian parents, autism detection is slow, confusing, and expensive. Many children are diagnosed only at age 6–7—far beyond the golden window for effective intervention.
Aignosis aims to change this entirely.
Whenever a paediatrician or teacher notices early behavioural signs—like limited eye contact—a five-minute screening video is shown to the child. The webcam tracks:
●Eye movements
●Visual attention
●Facial expressions
●Emotional responses
●Behavioural biomarkers
The AI model then analyses all this data and delivers a risk assessment report in just 2 minutes.
The tool currently offers 91% accuracy and 89% sensitivity—a huge leap for early neurodevelopmental screening.
The Science Behind the Breakthrough
The system uses advanced eye-tracking algorithms and behavioural analytics through standard cameras—meaning no special equipment, no invasive tests, and no hospital-grade machinery.
“It is fast, objective, and accessible,” says Gaural Gupta. “Our goal is to reach the first point of contact—paediatric clinics, preschools, and community health centres—so parents never lose precious years before diagnosis.”
Early Intervention Changes Lives — Aignosis Wants to Ensure Every Child Gets That Chance
Autism isn’t curable, Gupta clarifies, but it is highly manageable if support begins early. Studies show that up to 75% of children receiving early therapy can join mainstream schooling, participate fully in society, and grow into independent adults.
This is where Aignosis’ purpose lies—ensuring no child misses out on early help simply because the family didn’t know.
Affordable for Parents, Accessible for India
Aignosis follows a B2B model, providing its platform to clinics and preschools. For parents, the typical cost of autism diagnosis in India ranges from ₹500–₹1,000, depending on the city.
Once a risk is detected, the company connects the family to its network of trusted partner therapy centres.
Real Impact Already Visible
Though still in pre-revenue mode, the startup has begun touching lives.
During a preschool screening camp in Jaipur, the AI system flagged early signs in a young girl. She was immediately referred to a therapy centre and has already begun structured intervention.
“Had this gone unnoticed,” Gupta explains, “she might have missed the critical early-development window. Early action can change her entire life trajectory.”
Aignosis: A Jaipur Innovation with National Potential
The company’s vision is bold and deeply human—to bridge India’s diagnosis gap, especially in underserved communities where awareness and access remain low.
With its simple, scalable and science-backed tool, Aignosis is on track to revolutionise early autism detection for millions of Indian families.
